Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Orexigen® Therapeutics and Takeda Enter Into Partnership to Commercialize Contrave® in North America

September 2, 2010 By Bio-Medicine.Org

SAN DIEGO and OSAKA, Japan, Sept. 2 /PRNewswire-FirstCall/ —
Orexigen® Therapeutics, Inc. (Nasdaq:
OREX) and Takeda Pharmaceutical Company Limited (TSE: 4502),
today announced that they have entered into an exclusive
partnership to develop and commercialize Contrave® (naltrexone
SR/bupropion SR), Orexigen’s investigational drug for the treatment
of obesity, in the United States, Canada and Mexico.

Contrave is a combination therapy believed to address both
biological and behavioral drivers of obesity. The central pathways
targeted by this treatment are involved in controlling the balance
of food intake and metabolism, and regulating reward-based eating
behavior.  Orexigen submitted a New Drug Application (NDA) to
the U.S. Food and Drug Administration (FDA) for Contrave on March
31, 2010 and the Prescription Drug User Fee Act (PDUFA) action date
has been set for January 31, 2011.

Under the terms of the agreement, Orexigen will receive an
upfront cash payment of $50 million from Takeda, and Takeda will
obtain an exclusive marketing right from Orexigen in the United
States, Mexico and Canada while Orexigen retains the right to
co-promote with Takeda in the United States. Orexigen will be
eligible to receive payments of over $1 billion upon achieving
certain regulatory and sales-based milestones. Assuming Contrave is
commercialized, Takeda will pay tiered double-digit royalty
payments on net sales in the Territory.

Under the terms of the agreement, Orexigen and Takeda will work
together on ongoing development of the product, with Orexigen
leading pre-approval activities, and Takeda leading post-approval
activities.  The parties will share in the costs of any future
development of the product.

“Takeda is an ideal partner for Contrave given its proven track
record in commercializing innovative medicines and its commitment
to the treatment of

‘/>”/>

SOURCE

Related Articles Read More >

Dexcom One
How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7
A portrait of Stryker executive Siddarth Satish
How Stryker includes users for product design in the digital age
A Medtronic HVAD pump opened up to show the inner workings
Medtronic investigates HVAD pump welds after patient deaths
Galien Foundation 2022 nominees
18 of the world’s most innovative medical technologies

DeviceTalks Weekly.

May 20, 2022
DeviceTalks Boston Post-Game – Editors’ Top Moments, Insulet’s Eric Benjamin on future of Omnipod 5
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech